You don't get the science and product that's ok. My problem with this release is I don't understand how it is any different from the last preliminary release on BIT225 and it's effect in cART HIV suppression treatment. We were supposed to receive all of the data presented in a way that shareholders can understand. If this is supposed to be that release, then something is very fishy. Can anyone really point out the difference between this and the last "Preliminary results" release?
You don't get the science and product that's ok. My problem with...
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
